SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT00969137

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Sensitivity to Intravenous Nicotine: Genetic Moderators

To determine if the mu opioid receptor gene (OPRM1) A118G polymorphism moderates the subjective-rewarding effects of intravenous (IV) nicotine in male and female smokers. The subjective effects of nicotine will be measured with a Drug Effects Questionnaire, including the ratings of "good effects" and "drug liking". We hypothesize that smokers with the AG/GG genotype for the OPRM1 A118G will have attenuated subjective-rewarding effects from IV nicotine when compared to those with AA genotype.

NCT00969137 Nicotine Dependence
MeSH:Tobacco Use Disorder

2 Interventions

Name: saline

Description: intravenous saline
Type: Drug
Group Labels: 1


Name: Nicotine

Description: Intravenous nicotine
Type: Drug
Group Labels: 1


Primary Outcomes

Measure: primary hypotheses will test the influence of OPRM1 A118G status on subjective responses to IV nicotine, which will be measured with the drug effects questionnaire (DEQ).

Time: Injections 30 minutes apart

Purpose: Health Services Research

Allocation: Randomized

Crossover Assignment

There is one SNP


1 rs16969968

In addition, the association of the G398A polymorphism of the CHRNA5 gene (rs16969968) with maximal response to nicotinic agonists justifies examination of this SNP as a moderator of IV nicotine sensitivity in humans (Bierut et al. 2008).

The frequency of rs16969968 SNP ranges from 35%-42% among those of European ancestry, making it feasible to examine this variation in our subject sample.

HPO Nodes